CD8A and neoplasm: We found that the majority (CAR1, CAR2, CAR4, CAR5) but not all of our CAR T candidates had potent anti-tumor activity, and exhibited CD4:CD8 ratios of ~1.5 (Supplementary Fig. 1a, b).